个体化药物研发中的战略研发交易。

Strategic R&D transactions in personalized drug development.

机构信息

Life Innovation Design Laboratory, Graduate School of Technology Management, Ritsumeikan University, 2-150, Iwakuracho, Ibaraki-shi, Osaka 567-8570, Japan.

Faculty of Business Administration, Ritsumeikan University, 2-150, Iwakuracho, Ibaraki-shi, Osaka 567-8570, Japan.

出版信息

Drug Discov Today. 2018 Jul;23(7):1334-1339. doi: 10.1016/j.drudis.2018.03.009. Epub 2018 Mar 21.

DOI:10.1016/j.drudis.2018.03.009

PMID:29574213

Abstract

Although external collaboration capability influences the development of personalized medicine, key transactions in the pharmaceutical industry have not been addressed. To explore specific trends in interorganizational transactions and key players, we longitudinally surveyed strategic transactions, comparing them with other advanced medical developments, such as antibody therapy, as controls. We found that the financing deals of start-ups have surged over the past decade, accelerating intellectual property (IP) creation. Our correlation and regression analyses identified determinants of financing deals among alliance deals, acquisition deals, patents, research and development (R&D) licenses, market licenses, and scientific papers. They showed that patents positively correlated with transactions, and that the number of R&D licenses significantly predicted financing deals. This indicates, for the first time, that start-ups and investors lead progress in personalized medicine.

摘要

尽管外部协作能力影响着个性化医疗的发展，但制药行业的关键交易尚未得到解决。为了探索组织间交易和关键参与者的具体趋势，我们对战略交易进行了纵向调查，将其与抗体疗法等其他先进医疗发展进行了比较。我们发现，过去十年来，初创企业的融资交易激增，加速了知识产权（IP）的创造。我们的相关和回归分析确定了联盟交易、收购交易、专利、研发（R&D）许可证、市场许可证和科学论文之间融资交易的决定因素。结果表明，专利与交易呈正相关，R&D 许可证数量显著预测了融资交易。这首次表明，初创企业和投资者引领了个性化医疗的进步。